Ka. Dugi et al., In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL, ART THROM V, 20(3), 2000, pp. 793-800
To investigate the in vivo role that hepatic lipase (HL) plays in HDL metab
olism independently of its lipolytic function, recombinant adenovirus (rAdV
) expressing native HL, catalytically inactive HL (HL-145G), and luciferase
control was injected in HL-deficient mice. At day 4 after infusion of 2x10
(8) plaque-forming units of rHL-AdV and rHL-145G-AdV, similar plasma concen
trations were detected in postheparin plasma (HL=8.4+/-0.8 mu g/mL and HL-1
45G= 8.3+018 mu g/mL). Mice expressing HL had significant reductions of cho
lesterol (- 76%), phospholipids (PL; -68%), HDL cholesterol (-79%), apolipo
protein (apo) A-I (-45%), and apoA-II (-59%; P<0.05 for all), whereas mice
expressing HL-145G decreased their cholesterol (-49%), PL (-40%), HDL chole
sterol (-42%), and apoA-II (-89%; P<0.005 for all) but had no changes in ap
oA-I. The plasma kinetics of I-125-labeled apoA-I HDL, I-131-labeled apoA-I
I HDL, and [H-3]cholesteryl ester (CE) HDL revealed that compared with mice
expressing luciferase control (fractional catabolic rate [FCR] in d(-1): a
poA-I HDL=1.3+0.1; apoA-II HDL=2.1+/-0; CE HDL=4.1+/-0.7), both HL and HL-1
45G enhanced the plasma clearance of CEs and apoA-II present in HDL (apoA-I
I HDL=5.6+/-0.5 and 4.4+/-0.2; CE HDL=9.3+/-0.0 and 8.3+/-1.1, respectively
), whereas the clearance of apoA-I HDL was enhanced in mice expressing HL (
FCR=4.6+/-0.3) but not HL-145G (FCR=1.4+/-0.4). These combined findings dem
onstrate that both lipolytic and nonlipolytic functions of HL are important
for HDL metabolism in vivo. Our study provides, for the first time, in viv
o evidence for a role of HL in HDL metabolism independent of lipolysis and
provides new insights into the role of HL in facilitating distinct metaboli
c pathways involved in the catabolism of apoA-I- versus apoA-II-containing
HDL.